5 documents found, page 1 of 1
Focused Neuroprotection in Parkinson's Disease: Effects of N-Acetylcysteine and...
Silva, Rita Caridade; Araújo, B.; Vilaça-Ferreira, A. C.; Vilela, C.; Teixeira, C.; Martins-Macedo, J.; Soares-Guedes, C.; Gomes, Eduardo D.Parkinson’s Disease (PD) is characterized by a progressive degeneration of dopaminergic neurons (DAn) in the brain, leading to severe symptomatology. Current treatments mainly address motor symptoms rather than preventing DAn damage or degeneration. Hence, there is an urgent need for novel strategies, particularly those that can combine neuroprotective and neuroregenerative approaches [1]. Drug repurposing is a...
From the gut to the brain: Is microbiota a new paradigm in Parkinson’s disease ...
Vilela, Cristiana; Araújo, Bruna; Guedes, Carla; Silva, Rita Caridade; Macedo, Joana Martins; Teixeira, Catarina; Gomes, Eduardo; Prudêncio, CristinaParkinson’s disease (PD) is recognized as the second most prevalent primary chronic neurodegenerative disorder of the central nervous system. Clinically, PD is characterized as a movement disorder, exhibiting an incidence and mortality rate that is increasing faster than any other neurological condition. In recent years, there has been a growing interest concerning the role of the gut microbiota in the etiology...
Modulation of brain structure and motor function by safinamide multimodal actio...
Araújo, Bruna; Campos, Jonas; Silva, Rita Caridade; Pinheiro, Bárbara Mendes; Marques, Raquel; Barata, Sandra; Lima, Rui; Macedo, Joana MartinsTo date, no neuroprotective/disease-modifying strategy has been approved as a Parkinson’s Disease (PD) therapy, because of the‘one-disease-one-target’ view that has been followed. New drug-based therapeutic routes, namely Safinamide, have been introduced as a promising multimodal drug combining dopaminergic and non-dopaminergic (neuroprotective) actions, representing a new potential alternative therapy to preve...
Neuroinflammation and Parkinson’s disease - from neurodegeneration to therapeut...
Araújo, Bruna; Silva, Rita Caridade; Soares-Guedes, Carla; Martins-Macedo, Joana; Gomes, Eduardo Domingos Correia; Monteiro, SusanaParkinson’s disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Clinically, it is characterized by a progressive degeneration of dopaminergic neurons (DAn), resulting in severe motor complications. Preclinical and clinical studies have indicated that neuroinflammation can play a role in PD pathophysiology, being associated with its onset and progression. Nevertheless, several key poi...
Combining stem cells secretome and N-acetylcysteine to Parkinson's Disease mode...
Silva, Rita CaridadeA doença de Parkinson (DP) é uma doença neurodegenerativa progressiva caracterizada por uma perda maciça de neurónios dopaminérgicos (nDA), levando ao aparecimento de várias deficiências motoras. O tratamento atual é focado na minimização dos sintomas através da administração de levodopa, em vez de prevenir os danos neuronais. Neste sentido, o uso e desenvolvimento de estratégias neuroprotetoras/modificadoras d...